These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9541080)

  • 21. Cost effectiveness and projected national impact of colorectal cancer screening in France.
    Hassan C; Benamouzig R; Spada C; Ponchon T; Zullo A; Saurin JC; Costamagna G
    Endoscopy; 2011 Sep; 43(9):780-93. PubMed ID: 21623557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
    Heresbach D; Chauvin P; Grolier J; Josselin JM
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimates of costs and effects of screening for colorectal cancer in the United States.
    Byers T; Gorsky R
    Cancer; 1992 Sep; 70(5 Suppl):1288-95. PubMed ID: 1387342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Determination of cost-effective strategies in colorectal cancer screening].
    Dervaux B; Eeckhoudt L; Lebrun T; Sailly JC
    Rev Epidemiol Sante Publique; 1992; 40(5):296-306. PubMed ID: 1480806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds.
    Jørgensen OD; Kronborg O; Fenger C
    Gut; 2002 Jan; 50(1):29-32. PubMed ID: 11772963
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomised study of screening for colorectal cancer with faecal-occult-blood test.
    Kronborg O; Fenger C; Olsen J; Jørgensen OD; Søndergaard O
    Lancet; 1996 Nov; 348(9040):1467-71. PubMed ID: 8942774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening.
    Joseph AM; Crowson TW; Rich EC
    J Gen Intern Med; 1988; 3(2):132-8. PubMed ID: 3128650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Health economics analysis of colorectal screening].
    Boncz I; Sebestyén A; Dózsa C; Pál M; Sándor J; Palásti J; Betlehem J; Ember I
    Magy Onkol; 2004; 48(2):111-5. PubMed ID: 15351803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What is the most cost-effective screening regimen for colon cancer?
    Griffith S; Kane KY
    J Fam Pract; 2001 Jan; 50(1):13. PubMed ID: 11195472
    [No Abstract]   [Full Text] [Related]  

  • 31. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis.
    Ladabaum U; Chopra CL; Huang G; Scheiman JM; Chernew ME; Fendrick AM
    Ann Intern Med; 2001 Nov; 135(9):769-81. PubMed ID: 11694102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for colorectal cancer: what are the costs?
    Weller D; Moss J; Hiller J; Thomas D; Edwards J
    Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for colorectal cancer: which test can we afford?
    Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for colorectal cancer using the faecal occult blood test, Hemoccult.
    Hewitson P; Glasziou P; Irwig L; Towler B; Watson E
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD001216. PubMed ID: 17253456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case-control study evaluating occult blood screening for colorectal cancer with hemoccult test and an immunochemical hemagglutination test.
    Saito H; Soma Y; Nakajima M; Koeda J; Kawaguchi H; Kakizaki R; Chiba R; Aisawa T; Munakata A
    Oncol Rep; 2000; 7(4):815-9. PubMed ID: 10854550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cost-effectiveness analysis of cervical cancer screening: health policy implications.
    Gyrd-Hansen D; Hølund B; Andersen P
    Health Policy; 1995 Oct; 34(1):35-51. PubMed ID: 10151964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data.
    Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y
    Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
    Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
    J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.